David Tyler Severson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
David Tyler Severson has a total of 337 co-authors. Here are the top co-authors by number of shared publications:
Raphael Bueno
19 shared publicationsA. Gordon Robertson
18 shared publicationsAchim A. Jungbluth
18 shared publicationsAliya N. Husain
18 shared publications- Anne S. Tsao
The University of Texas MD Anderson Cancer Center
18 shared publications Assunta De Rienzo
The Thoracic Surgery Oncology laboratory and the International Mesothelioma Program (www.impmeso.org), Division of Thoracic Surgery and the Lung Center, Brigham and Women’s Hospital, and Harvard Medical School
18 shared publications
Latest Publications
- Open Access
- 7 May 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (5) , e014671
Endogenous neoantigen-specific antibodies mediate antitumor responses and determine vaccine efficacy
Background: The contribution of B cells to antitumor immunity remains controversial, with studies reporting varied effects across cancer types. Even less is known about the role of the endogenous humoral response, including when tumor-elicited antibodies are protective, when they are deleterious, and how they might be modulated to influence antitumor immunity. Critically, it remains unclear whether specific antigenic features govern the efficacy of humoral immune responses against cancer. We aim to define the conditions under which endogenous antibodies mediate antitumor immunity and to leverage these principles to improve neoantigen-directed immunotherapies, including cancer vaccines. Methods: We performed a pan-cancer analysis of The Cancer Genome Atlas (TCGA) to assess associations between intratumoral IgG and clinical outcomes. Using syngeneic mouse tumor models expressing membrane or cytoplasmic neoantigens, we examined how antigen localization influences endogenous antibody responses. We evaluated strategies to enhance humoral immunity via cytokine and chemokine modulation and assessed antibody responses in the context of cancer vaccination. Results: Our pan-cancer TCGA analysis revealed marked heterogeneity in the prognostic impact of intratumoral IgG. In vivo, expression of membrane-localized, but not cytoplasmic, neoantigens drove potent class-switched IgG responses, activated myeloid cells, and restricted tumor growth independently of CD8 T cells. Notably, membrane-restricted antigen expression was sufficient to convert tumor types such as colorectal cancer, where IgG correlates with poor prognosis, into settings in which antibodies mediate tumor suppression. These effects required CD4 T-cell help, antigen-specific IgG, and Fc receptor engagement. Enhancing B-cell recruitment (C-X-C motif chemokine ligand 13) or B-cell help (interleukin (IL)-21) further amplified antibody-mediated tumor control, with co-expression providing the strongest benefit. Finally, we establish that antigen localization dictates vaccine efficacy: the point-mutated trophoblast cell-surface antigen 2 (Trop2) T256R, which exhibits impaired membrane localization and reduced antibody binding relative to wild-type Trop2, failed to elicit comparable vaccine-induced tumor control. Conclusions: These findings identify antigen subcellular localization as a key regulator of endogenous antibody-mediated antitumor immunity and cancer vaccine efficacy, providing a mechanistic framework for leveraging humoral immunity in immunotherapeutic strategies. CXCL13 and IL-21 emerge as candidate approaches to selectively enhance antibody-mediated tumor control in settings where membrane-bound antigens are present.
- 7 May 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (5) , e014671
Open AccessEndogenous neoantigen-specific antibodies mediate antitumor responses and determine vaccine efficacy
Background: The contribution of B cells to antitumor immunity remains controversial, with studies reporting varied effects across cancer types. Even less is known about the role of the endogenous humoral response, including when tumor-elicited antibodies are protective, when they are deleterious, and how they might be modulated to influence antitumor immunity. Critically, it remains unclear whether specific antigenic features govern the efficacy of humoral immune responses against cancer. We aim to define the conditions under which endogenous antibodies mediate antitumor immunity and to leverage these principles to improve neoantigen-directed immunotherapies, including cancer vaccines. Methods: We performed a pan-cancer analysis of The Cancer Genome Atlas (TCGA) to assess associations between intratumoral IgG and clinical outcomes. Using syngeneic mouse tumor models expressing membrane or cytoplasmic neoantigens, we examined how antigen localization influences endogenous antibody responses. We evaluated strategies to enhance humoral immunity via cytokine and chemokine modulation and assessed antibody responses in the context of cancer vaccination. Results: Our pan-cancer TCGA analysis revealed marked heterogeneity in the prognostic impact of intratumoral IgG. In vivo, expression of membrane-localized, but not cytoplasmic, neoantigens drove potent class-switched IgG responses, activated myeloid cells, and restricted tumor growth independently of CD8 T cells. Notably, membrane-restricted antigen expression was sufficient to convert tumor types such as colorectal cancer, where IgG correlates with poor prognosis, into settings in which antibodies mediate tumor suppression. These effects required CD4 T-cell help, antigen-specific IgG, and Fc receptor engagement. Enhancing B-cell recruitment (C-X-C motif chemokine ligand 13) or B-cell help (interleukin (IL)-21) further amplified antibody-mediated tumor control, with co-expression providing the strongest benefit. Finally, we establish that antigen localization dictates vaccine efficacy: the point-mutated trophoblast cell-surface antigen 2 (Trop2) T256R, which exhibits impaired membrane localization and reduced antibody binding relative to wild-type Trop2, failed to elicit comparable vaccine-induced tumor control. Conclusions: These findings identify antigen subcellular localization as a key regulator of endogenous antibody-mediated antitumor immunity and cancer vaccine efficacy, providing a mechanistic framework for leveraging humoral immunity in immunotherapeutic strategies. CXCL13 and IL-21 emerge as candidate approaches to selectively enhance antibody-mediated tumor control in settings where membrane-bound antigens are present.
- Open Access
Comprehensive multi-site profiling of the malignant pleural mesothelioma micro-environment identifies candidate molecular determinants of histopathologic type
Pleural mesothelioma (PM) comprises sarcomatoid, epithelioid and biphasic histologic subtypes. Bulk PM RNA-sequencing identifies a histology-associated molecular gradient with features of epithelial-mesenchymal (EM) transition but cannot parse malignant, stromal, and immune tumor components. The mechanisms driving PM malignant cell phenotype and associated histology is not well-characterized. Here, we use single-cell RNA-sequencing (scRNA-seq) paired with exome, bulk RNA-sequencing, and histologic analysis of adjacent samples to characterize malignant cell EM state, parse the tumor microenvironment (TME), and identify candidate drivers of PM cell fate. We observe EM variation in malignant cells analogous to bulk samples. We characterize epithelioid and sarcomatoid malignant cell programs and identify a new uncommitted malignant cell EM phenotype enriched in biphasic histology samples. Using inferred CNVs we observe that single individual PM clones consist of cells exhibiting all three EM cell states. We find that distinct non-malignant microenvironments associated with tumors consisting of mostly cells in each state, and identify WNT inhibition, GAS6-AXL , and HBEGF-EGFR signaling as pathways associated with distinct EM cell states. These findings provide deeper insight into the molecular drivers of PM malignant cells and identify non-malignant cell signals as potential EMT and growth drivers in PM.
Open AccessComprehensive multi-site profiling of the malignant pleural mesothelioma micro-environment identifies candidate molecular determinants of histopathologic type
Pleural mesothelioma (PM) comprises sarcomatoid, epithelioid and biphasic histologic subtypes. Bulk PM RNA-sequencing identifies a histology-associated molecular gradient with features of epithelial-mesenchymal (EM) transition but cannot parse malignant, stromal, and immune tumor components. The mechanisms driving PM malignant cell phenotype and associated histology is not well-characterized. Here, we use single-cell RNA-sequencing (scRNA-seq) paired with exome, bulk RNA-sequencing, and histologic analysis of adjacent samples to characterize malignant cell EM state, parse the tumor microenvironment (TME), and identify candidate drivers of PM cell fate. We observe EM variation in malignant cells analogous to bulk samples. We characterize epithelioid and sarcomatoid malignant cell programs and identify a new uncommitted malignant cell EM phenotype enriched in biphasic histology samples. Using inferred CNVs we observe that single individual PM clones consist of cells exhibiting all three EM cell states. We find that distinct non-malignant microenvironments associated with tumors consisting of mostly cells in each state, and identify WNT inhibition, GAS6-AXL , and HBEGF-EGFR signaling as pathways associated with distinct EM cell states. These findings provide deeper insight into the molecular drivers of PM malignant cells and identify non-malignant cell signals as potential EMT and growth drivers in PM.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Table S6 from Integrative Molecular Characterization of Malignant Pleural Mesothelioma
Table S6 contains results from the analysis of DNA methylation in SETD2 mutated and BAP1 inactivated samples.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from Integrative Molecular Characterization of Malignant Pleural Mesothelioma
Table S6 contains results from the analysis of DNA methylation in SETD2 mutated and BAP1 inactivated samples.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Table S1 from Integrative Molecular Characterization of Malignant Pleural Mesothelioma
Table S1 contains cohort description, Master Patient Table and MutSigCV results.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Integrative Molecular Characterization of Malignant Pleural Mesothelioma
Table S1 contains cohort description, Master Patient Table and MutSigCV results.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Table S3 from Integrative Molecular Characterization of Malignant Pleural Mesothelioma
Table S3 contains the karyotypes of 16 genome-wide LOH MPM cases from the BWH cohort.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Integrative Molecular Characterization of Malignant Pleural Mesothelioma
Table S3 contains the karyotypes of 16 genome-wide LOH MPM cases from the BWH cohort.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Table S6 from Integrative Molecular Characterization of Malignant Pleural Mesothelioma
Table S6 contains results from the analysis of DNA methylation in SETD2 mutated and BAP1 inactivated samples.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from Integrative Molecular Characterization of Malignant Pleural Mesothelioma
Table S6 contains results from the analysis of DNA methylation in SETD2 mutated and BAP1 inactivated samples.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Integrative Molecular Characterization of Malignant Pleural Mesothelioma
Supplementary materials and methods, as well as supplementary figures S1-S7.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Integrative Molecular Characterization of Malignant Pleural Mesothelioma
Supplementary materials and methods, as well as supplementary figures S1-S7.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Table S5 from Integrative Molecular Characterization of Malignant Pleural Mesothelioma
Table S5 contains detailed miRs and lncRNAs results.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Integrative Molecular Characterization of Malignant Pleural Mesothelioma
Table S5 contains detailed miRs and lncRNAs results.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Table S5 from Integrative Molecular Characterization of Malignant Pleural Mesothelioma
Table S5 contains detailed miRs and lncRNAs results.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Integrative Molecular Characterization of Malignant Pleural Mesothelioma
Table S5 contains detailed miRs and lncRNAs results.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Integrative Molecular Characterization of Malignant Pleural Mesothelioma
Malignant pleural mesothelioma (MPM) is a highly lethal cancer of the lining of the chest cavity. To expand our understanding of MPM, we conducted a comprehensive integrated genomic study, including the most detailed analysis of BAP1 alterations to date. We identified histology-independent molecular prognostic subsets, and defined a novel genomic subtype with TP53 and SETDB1 mutations and extensive loss of heterozygosity. We also report strong expression of the immune-checkpoint gene VISTA in epithelioid MPM, strikingly higher than in other solid cancers, with implications for the immune response to MPM and for its immunotherapy. Our findings highlight new avenues for further investigation of MPM biology and novel therapeutic options.Significance:Through a comprehensive integrated genomic study of 74 MPMs, we provide a deeper understanding of histology-independent determinants of aggressive behavior, define a novel genomic subtype with TP53 and SETDB1 mutations and extensive loss of heterozygosity, and discovered strong expression of the immune-checkpoint gene VISTA in epithelioid MPM.See related commentary by Aggarwal and Albelda, p. 1508.This article is highlighted in the In This Issue feature, p. 1494
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Integrative Molecular Characterization of Malignant Pleural Mesothelioma
Malignant pleural mesothelioma (MPM) is a highly lethal cancer of the lining of the chest cavity. To expand our understanding of MPM, we conducted a comprehensive integrated genomic study, including the most detailed analysis of BAP1 alterations to date. We identified histology-independent molecular prognostic subsets, and defined a novel genomic subtype with TP53 and SETDB1 mutations and extensive loss of heterozygosity. We also report strong expression of the immune-checkpoint gene VISTA in epithelioid MPM, strikingly higher than in other solid cancers, with implications for the immune response to MPM and for its immunotherapy. Our findings highlight new avenues for further investigation of MPM biology and novel therapeutic options.Significance:Through a comprehensive integrated genomic study of 74 MPMs, we provide a deeper understanding of histology-independent determinants of aggressive behavior, define a novel genomic subtype with TP53 and SETDB1 mutations and extensive loss of heterozygosity, and discovered strong expression of the immune-checkpoint gene VISTA in epithelioid MPM.See related commentary by Aggarwal and Albelda, p. 1508.This article is highlighted in the In This Issue feature, p. 1494